The CSIR-Indian Institute of Chemical Technology (CSIR-IICT) recently signed an MoU with 101 Therapeutics, Israel for clinical trials for a medication to treat COVID-19 drug.
As per the three-year agreement, CSIR-IICT will be the knowledge partner for the clinical trial study and 101 Therapeutics, a CRO will manufacture the drug.
This is an intravenous macrophage-targeting drug conjugate that could be administered in the initial as well as later stages of the COVID infection. Phase 3 trials for the drug are likely to commence soon, post which the drug will be available in India for treatment of Covid and other infections like meningitis.
Dr D Shailaja, Chief Scientist & Chair, Business Development & Research Management on behalf of CSIR-IICT and Alec Goldberg on behalf of 101 Therapeutics, signed the MoU.
The post
You do not have permission to view link please Log in or Register
appeared first on
You do not have permission to view link please Log in or Register